Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply
Lancet Respir Med
.
2023 Jan;11(1):e7-e8.
doi: 10.1016/S2213-2600(22)00450-7.
Epub 2022 Dec 12.
Authors
Sheetal Maselkar
1
,
Alexandre Kiazand
1
,
Alison Templeton
2
,
Hugh Montgomery
3
,
Mark T Esser
4
Affiliations
1
Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD 20878-2204, USA.
2
Biometrics, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
3
Department of Medicine, University College London, London, UK.
4
Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD 20878-2204, USA. Electronic address: mark.esser@astrazeneca.com.
PMID:
36521509
PMCID:
PMC9779778
DOI:
10.1016/S2213-2600(22)00450-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal*
Humans
Substances
tixagevimab
cilgavimab
Antibodies, Monoclonal